4
Participants
Start Date
September 12, 2023
Primary Completion Date
August 20, 2024
Study Completion Date
November 1, 2024
1A46 Drug Substance
Cycle 1 which will consist of an initial dose given on C1D1 and an intermediate dose given on C1D8, followed by a maintenance dose beginning on C1D15 and continuing while the patient is treated at that dose level
Beijing Cancer Hospital, Beijing
Lead Sponsor
BioRay Pharmaceutical Co., Ltd.
INDUSTRY